Anal Squamous Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ANL017 MIFTS: 38	Anal Squamous Cell Carcinoma Categories: Cancer diseases, Gastrointestinal diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Anal Squamous Cell Carcinoma

MalaCards integrated aliases for Anal Squamous Cell Carcinoma:

Name: Anal Squamous Cell Carcinoma ¹¹ ¹⁴ ¹⁶ ⁷¹

Epidermoid Anal Carcinoma ¹¹

Carcinoma of Anal Margin ⁷¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases Skin diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:5525

NCIt ⁴⁹ C9161

SNOMED-CT ⁶⁸ 255084004

EFO ¹⁶ EFO_1000081

UMLS ⁷¹ C0349534 C1412036

Sources

Summaries for Anal Squamous Cell Carcinoma

Disease Ontology: ¹¹ An anal carcinoma that arises near the squamocolumnar junction.

MalaCards based summary: Anal Squamous Cell Carcinoma, also known as epidermoid anal carcinoma, is related to squamous cell carcinoma and papilloma. An important gene associated with Anal Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Immune response IL-23 signaling pathway and Malignant pleural mesothelioma. The drugs Nivolumab and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include t cells, cervix and endothelial, and related phenotype is cellular.

Sources

Related Diseases for Anal Squamous Cell Carcinoma

Diseases related to Anal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 506)

#	Related Disease	Score	Top Affiliating Genes
1	squamous cell carcinoma	30.7	TP53 PIK3CA KRT7 FBXW7 EGFR CDKN2A
2	papilloma	30.6	TP53 KRT7 EGFR CDKN2A
3	suppressor of tumorigenicity 3	30.4	TP53 CDKN2A
4	leiomyosarcoma	30.3	TP53 CDKN2A CD274
5	basaloid squamous cell carcinoma	30.2	TP53 KRT7 CDKN2A
6	lymphatic system disease	30.0	TP53 H2AC18 CD8A CD4
7	malignant peripheral nerve sheath tumor	29.7	TP53 KRT7 EGFR CDKN2A
8	cervical squamous cell carcinoma	29.7	TP53 PIK3CA FBXW7 EGFR CDKN2A
9	rectal benign neoplasm	29.7	TP53 PIK3CA KRT7 EGFR
10	exanthem	29.6	H2AC18 EGFR CD8A CD4 CD274
11	lymphoma, non-hodgkin, familial	29.6	TP53 PIK3CA H2AC18 CD8A CD4 CD274
12	anus cancer	29.5	ZNF582 WDR17 TP53 PIK3CA KRT7 H2AC18
13	basal cell carcinoma	29.5	TP53 KRT7 H2AC18 EGFR CDKN2A
14	human papillomavirus infectious disease	29.4	TP53 PIK3CA EGFR CDKN2A CD8A CD4
15	adenocarcinoma	29.3	TP53 PIK3CA KRT7 EGFR CDKN2A CD274
16	thymoma	29.2	TP53 KRT7 EGFR CDKN2A CD8A CD274
17	head and neck cancer	29.2	TP53 PIK3CA H2AC18 EGFR CDKN2A CD8A
18	adenoid cystic carcinoma	29.1	TP53 PIK3CA KRT7 FBXW7 EGFR CDKN2A
19	vaginal cancer	29.1	TP53 KRT7 EGFR CDKN2A CD8A CD4
20	lymphangioma	29.0	TP53 PIK3CA KRT7 H2AC18 EGFR CD8A
21	endometrial cancer	28.9	TP53 PIK3CA KRT7 H2AC18 FBXW7 EGFR
22	rectum adenocarcinoma	28.8	TP53 PIK3CA KRT7 FBXW7 EGFR CD8A
23	anus disease	28.7	ZNF582 TP53 PIK3CA KRT7 H2AC18 EGFR
24	cervix carcinoma	28.6	TP53 PIK3CA KRT7 H2AC18 EGFR CDKN2A
25	colon squamous cell carcinoma	11.3
26	anal canal carcinoma	10.5
27	anal canal squamous cell carcinoma	10.4
28	neutropenia	10.3
29	rare tumor	10.3
30	autoimmune cardiomyopathy	10.3	CD4 CD274
31	b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)	10.3	TP53 CDKN2A
32	hilar lung neoplasm	10.3	CD8A CD4
33	bizarre leiomyoma	10.3	TP53 CDKN2A
34	cervical basaloid squamous cell carcinoma	10.3	KRT7 CDKN2A
35	diarrhea	10.3
36	anus benign neoplasm	10.3	H2AC18 CDKN2A
37	inverted transitional papilloma	10.3	KRT7 CDKN2A
38	oral tuberculosis	10.3	CD8A CD4
39	early yaws	10.3	CD8A CD4
40	anal canal paget's disease	10.3	KRT7 CDKN2A
41	endometrial transitional cell carcinoma	10.3	KRT7 CDKN2A
42	ventilation pneumonitis	10.3	CD8A CD4
43	atrophic vulva	10.3	KRT7 CDKN2A
44	larynx squamous papilloma	10.3	TP53 CDKN2A
45	diffuse infiltrative lymphocytosis syndrome	10.3	CD8A CD4
46	wissler-fanconi syndrome	10.3	CD8A CD4
47	autoimmune lymphoproliferative syndrome, type iia	10.3	CD8A CD4
48	cervical mucinous adenocarcinoma	10.3	KRT7 CDKN2A
49	vulval paget's disease	10.3	KRT7 CDKN2A
50	encephalitozoonosis	10.3	CD8A CD4

Graphical network of the top 20 diseases related to Anal Squamous Cell Carcinoma:

Sources

Symptoms & Phenotypes for Anal Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Anal Squamous Cell Carcinoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	9.36	CD274 CD4 CD8A CDKN2A EGFR FBXW7

Sources

Drugs & Therapeutics for Anal Squamous Cell Carcinoma

Drugs for Anal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Nivolumab

Approved

Phase 3

946414-94-4

Fluorouracil

Approved

Phase 3

51-21-8

3385

Mitomycin

Approved

Phase 3

50-07-7

5746

Immune Checkpoint Inhibitors

Phase 3

Immunoglobulins

Phase 3

Antibodies

Phase 3

Panitumumab

Approved, Investigational

Phase 2

339177-26-3

Cetuximab

Approved

Phase 1, Phase 2

205923-56-4

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Avelumab

Approved, Investigational

Phase 1, Phase 2

1537032-82-8

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Fludarabine

Approved

Phase 1, Phase 2

75607-67-9, 21679-14-1

30751 657237

Cyclophosphamide

Approved, Investigational

Phase 1, Phase 2

50-18-0, 6055-19-2

2907

Aldesleukin

Approved

Phase 1, Phase 2

110942-02-4

ON 01910

Phase 2

Protein Kinase Inhibitors

Phase 2

Anti-Bacterial Agents

Phase 2

Alkylating Agents

Phase 2

Antibiotics, Antitubercular

Phase 2

Immunosuppressive Agents

Phase 2

Immunologic Factors

Phase 2

Vaccines

Phase 1, Phase 2

Albumin-Bound Paclitaxel

Phase 2

Antimitotic Agents

Phase 2

Tubulin Modulators

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Antimetabolites

Phase 2

Immunoglobulins, Intravenous

Phase 2

Immunoglobulin G

Phase 2

Angiogenesis Inhibitors

Phase 2

Antibodies, Monoclonal

Phase 2

Endothelial Growth Factors

Phase 2

Mitogens

Phase 2

Antiviral Agents

Phase 1, Phase 2

Anti-Retroviral Agents

Phase 1, Phase 2

Anti-Infective Agents

Phase 1, Phase 2

Anti-HIV Agents

Phase 1, Phase 2

Antirheumatic Agents

Phase 1

Antineoplastic Agents, Alkylating

Phase 1

Interleukin-2

Phase 1

Analgesics, Non-Narcotic

Phase 1

Analgesics

Phase 1

Cola

Interventional clinical trials:

(show all 24)

#	Name	Status	NCT ID	Phase	Drugs
1	A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Na�ve Metastatic Anal Cancer Patients	Recruiting	NCT04444921	Phase 3	Carboplatin;Paclitaxel
2	A Phase 3, Multicenter, Double-Blind Randomized Study of Mitomycin, 5-Fluorouracil and IMRT Combined With or Without Anti-PD-1 in Patients With Locally Advanced Anal Canal Squamous Carcinoma	Recruiting	NCT05374252	Phase 3	PD-1 inhibitor
3	Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma	Completed	NCT01285778	Phase 2	panitumumab, mytomicin C, 5-FU, radiation
4	A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma	Completed	NCT01807546	Phase 2	rigosertib
5	A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)	Recruiting	NCT04166318	Phase 2	Capecitabine;Fluorouracil;Mitomycin
6	A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 Monotherapy or in Combination With Cetuximab as a Salvage Regimen for Solid Tumors	Recruiting	NCT04616196	Phase 1, Phase 2	NKTR-255;Cetuximab
7	Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients	Recruiting	NCT05060471	Phase 2	Toripalimab
8	A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons	Recruiting	NCT02437851	Phase 2
9	A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.	Recruiting	NCT03260023	Phase 1, Phase 2	Avelumab
10	Risk-Adapted Therapy for HIV-Associated Anal Cancer	Recruiting	NCT04929028	Phase 2	Capecitabine;Fluorouracil;Mitomycin
11	ROAR-A: Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer	Recruiting	NCT05438836	Phase 2
12	InterAACT - An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5-Fluorouracil Versus Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease	Active, not recruiting	NCT02560298	Phase 2	Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel
13	A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid Tumors	Active, not recruiting	NCT03074513	Phase 2	Atezolizumab
14	A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers	Not yet recruiting	NCT05639972	Phase 1, Phase 2	Conditioning, E7 TCR-T cells, and aldesleukin
15	An Open-label, Phase II, Multi-cohort, 2-stage Trial to Evaluate the Efficacy and Safety of Regorafenib in Combination With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Pretreated Solid Cancers	Not yet recruiting	NCT05582031	Phase 2
16	A Phase 1 Study of LY2606368 in Patients With Advanced Cancer	Completed	NCT01115790	Phase 1	Prexasertib
17	A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors	Terminated	NCT04596033	Phase 1	IL-2;Fludarabine;Cyclophosphamide
18	Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy	Completed	NCT02145416
19	Proton Versus Photon Therapy in Anal Squamous Cell Carcinoma - Swedish Anal Carcinoma Study	Recruiting	NCT04462042
20	Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.	Recruiting	NCT03061435
21	Circulating HPV DNA in Cancers of the Anus and Uterine Cervix Treated With Definitive Radiation Therapy	Recruiting	NCT04857528
22	The Role of a 4-point Therapy Response Score With PET/CT Post Definitive Chemoradiation for Anal Squamous Cell Cancer: A Prospective Study	Recruiting	NCT05130073
23	ACTION HIV (Anal Cancer TherapIes and Outcomes iNitiative for Patients Living With and Without HIV): A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection	Not yet recruiting	NCT05328765
24	Prospective Validation Study Under CLIA-compliant SOPs for the Proprietary Rectal and Anal Cancer Protein Expression Assays	Terminated	NCT02407561

Search NIH Clinical Center for Anal Squamous Cell Carcinoma

Sources

Genetic Tests for Anal Squamous Cell Carcinoma

Sources

Anatomical Context for Anal Squamous Cell Carcinoma

Organs/tissues related to Anal Squamous Cell Carcinoma:

MalaCards : T Cells, Cervix, Endothelial, Lymph Node, Myeloid, Liver, Bone Marrow

Sources

Publications for Anal Squamous Cell Carcinoma

Articles related to Anal Squamous Cell Carcinoma:

(show top 50) (show all 542)

#	Title	Authors	PMID	Year
1	Failure of Initial Curative Treatment for Non-Metastatic Anal Squamous Cell Carcinoma: From Prognostic Factors Analysis to Stratified Treatment. ⁶²	Jaraudias C...Evesque L	35934635	2022
2	Impact of Time From Diagnosis to Treatment Start on the Outcomes of Patients With Nonmetastatic Anal Squamous Cell Carcinoma. ⁶²	Abdel-Rahman O...Ghosh S	36453694	2022
3	Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation. ⁶²	Yamasaki M...Takayama T	36409453	2022
4	Demographics and incidence of anal squamous cell carcinoma in people living in high HIV prevalence geographical areas. ⁶²	Brogden DRL...Mills SC	34887349	2022
5	The first comprehensive genomic characterization of rectal squamous cell carcinoma. ⁶²	Astaras C...Koessler T	36357817	2022
6	Characteristics and oncological results of epidermoid anal carcinoma: Comparison analysis between immunocompetent and immunosuppressed patients. ⁶²	Saralegui Ansorena Y...Aguirre Allende I	35850478	2022
7	Successful Management of Anal Squamous Cell Carcinoma With Liver and Ovary Metastases: A Case Report. ⁶²	Mitsuura C...Baba H	36309369	2022
8	Influence of radiation treatment technique (IMRT vs. 3D-RT) on acute toxicity and prognostic factors for survival for anal cancer. ⁶²	Sauter C...Dapper H	36402828	2022
9	Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer. ⁶²	Lukovic J...Kim JJ	36455685	2022
10	Artificial intelligence and high-resolution anoscopy: automatic identification of anal squamous cell carcinoma precursors using a convolutional neural network. ⁶²	Saraiva MM...de Parades V	35986806	2022
11	Concurrent Chemo-radiotherapy in Anal Squamous Cell Carcinoma: A Retrospective Review of a Tertiary Centre Experience. ⁶²	Patel C...Giridharan S	36269537	2022
12	A nationwide longitudinal study on risk factors for progression of anal intraepithelial neoplasia grade 3 to anal cancer. ⁶²	Faber MT...Kjaer SK	35657350	2022
13	The effect of human immunodeficiency virus and human papillomavirus strain diversity on the progression of anal squamous intraepithelial lesions. ⁶²	Bushara O...Yang GY	35803414	2022
14	Role of local therapy in the management of patients with metastatic anal squamous cell carcinoma: a National Cancer Database study. ⁶²	Atallah RP...Alese OB	36388688	2022
15	Colorectal Surgery Practice, Training, and Research in Low-Resource Settings. ⁶²	Chu KM...Forgan T	36111082	2022
16	Management of anal squamous cell carcinoma and its recurrences. ⁶²	Teran-Lopez A...Llerena J	35599084	2022
17	Author's reply: "Management of anal squamous cell carcinoma and its recurrences". ⁶²	Lepage C...Jooste V	35811231	2022
18	Pretreatment colostomy in patients with anal squamous cell carcinoma: Risk factors for a permanent stoma. ⁶²	Sobrado LF...Nahas SC	35639271	2022
19	Impact of HIV on Anal Squamous Cell Carcinoma Rates in the United States, 2001-2015. ⁶²	Zhang ER...Shiels MS	35575389	2022
20	Our experience in the short-term diagnostic-therapeutic management of the patient with anal dysplasia. ⁶²	Galan Martinez C...Targarona Soler EM	36152962	2022
21	Programmed Death Ligand-1 Expression Is Associated With Poorer Survival in Anal Squamous Cell Carcinoma. ⁶²	Monsrud AL...Krishnamurti U	34936703	2022
22	Trends in utilization of first-line palliative treatments for anal squamous cell carcinoma. ⁶²	Radhakrishnan SJ...Kazmi SM	36082966	2022
23	Development and validation of prognostic models for anal cancer outcomes using distributed learning: protocol for the international multi-centre atomCAT2 study. ⁶²	Theophanous S...atomCAT consortium	35922837	2022
24	Anal squamous cell carcinoma in HIV patients with HPV-16 condylomas: a serious complication in immunocompromised patients. ⁶²	Celada-Sendino M...Florez-Diez P	35297261	2022
25	Combined PET-CT and MRI for response evaluation in patients with squamous cell anal carcinoma treated with curative-intent chemoradiotherapy. ⁶²	Adusumilli P...Scarsbrook AF	35274187	2022
26	The Prognostic Role of Baseline Eosinophils in HPV-Related Cancers: a Multi-institutional Analysis of Anal SCC and OPC Patients Treated with Radical CT-RT. ⁶²	Rimini M...Casadei-Gardini A	35915202	2022
27	Robotic beyond total mesorectal excision surgery for primary and recurrent pelvic malignancy: Feasibility and short-term outcomes. ⁶²	Larach JT...Warrier SK	35373888	2022
28	Anal intraepithelial neoplasia: a review of terminology, differential diagnoses, and patient management. ⁶²	Vyas M...Gonzalez RS	35843339	2022
29	Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab: A case report. ⁶²	Agrawal R...Chen Y	36051149	2022
30	Anal cytology screening in men who have sex with men with HIV at a university hospital in Bogotá, Colombia. ⁶²	Ordonez-Blanco IT...Valderrama-Beltran SL	35491739	2022
31	Long-term Patterns of Failure and the Value of Blood Prognostic Markers in Anal Cancers Treated With Intensity-Modulated Radiation Therapy. ⁶²	Sia J...Ngan SY	34799240	2022
32	Short-term effectiveness and tolerability of carbon dioxide laser for anal high-grade squamous intraepithelial lesions in individuals living with HIV. ⁶²	Fuertes I...Blanco JL	35611790	2022
33	Leukocyte subtyping predicts for treatment failure and poor survival in anal squamous cell carcinoma. ⁶²	Principe DR...Gantt G	35751111	2022
34	Metastatic Anal Squamous Cell Carcinoma Presenting as an Indeterminate Biliary Stricture Diagnosed By Cholangioscopy. ⁶²	Nahar R...Kowalski T	35765678	2022
35	Stage IV anal canal squamous cell carcinoma with long-term survival: a case report. ⁶²	Sawai K...Maeda H	35723765	2022
36	Detection of Anal Intraepithelial Neoplasia and Anal Squamous Cell Carcinoma on Colonoscopy. ⁶²	Voss JK...Chedid VG	35756724	2022
37	Anorectal pathology in the HIV population: a guide for radiologists. ⁶²	Vos D...Smith DA	35284963	2022
38	Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. ⁶²	Marabelle A...Delord JP	35114169	2022
39	Increased risk of genital warts in inflammatory bowel disease: A Danish registry-based cohort study (1996-2018). ⁶²	Elmahdi R...Jess T	35297191	2022
40	Anal squamous cell carcinoma: a retrospective case series. ⁶²	Houlihan OA...O'Neill BDP	33977391	2022
41	Treatment strategy for vertebral metastases from anal squamous cell carcinoma: a comprehensive literature review and case report. ⁶²	Agosti E...Fontanella MM	35369848	2022
42	Perineal Reconstruction With the Profunda Artery Perforator Flap. ⁶²	Arquette C...Momeni A	34510081	2022
43	The influence of HIV status on the duration of chemoradiotherapy for anal squamous cell carcinoma. ⁶²	Zubi AR...Surridge DJ	35451264	2022
44	Prognostic Value of Fusobacterium nucleatum after Abdominoperineal Resection for Anal Squamous Cell Carcinoma. ⁶²	Hilmi M...Bieche I	35406380	2022
45	Mitomycin-Induced Thrombotic Thrombocytopenic Purpura Treated Successfully With Plasmapheresis and Steroid: A Case Report. ⁶²	Khaja M...Yapor L	35494991	2022
46	Carcinogenesis and Cancer Progression in De Novo Anal Squamous Cell Carcinoma After Organ Transplantation: A Systematic Review. ⁶²	Borin A...Carraro A	35282809	2022
47	Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG). ⁶²	Martin D...Fokas E	34999135	2022
48	Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. ⁶²	Holliday EB...Messick CA	35305097	2022
49	New approaches in palliative systemic therapy of anal squamous cell carcinoma. ⁶²	Lohynska R...Pechacova Z	35760571	2022
50	Hepatic metastasis of anal squamous cell carcinoma. ⁶²	Ng ZQ...Jacob A	35039378	2022

Sources

Genes for Anal Squamous Cell Carcinoma

Genes related to Anal Squamous Cell Carcinoma (0 elite genes):

(show all 17)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	6.24	DISEASES inferred ¹⁴
2	WDR17	WD Repeat Domain 17	Protein Coding	6.23	DISEASES inferred ¹⁴
3	ZNF582	Zinc Finger Protein 582	Protein Coding	5.78	DISEASES inferred ¹⁴
4	CD274	CD274 Molecule	Protein Coding	5.68	DISEASES inferred ¹⁴
5	CD4	CD4 Molecule	Protein Coding	5.63	DISEASES inferred ¹⁴
6	H2AC18	H2A Clustered Histone 18	Protein Coding	5.63	DISEASES inferred ¹⁴ ¹⁴
7	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	5.51	DISEASES inferred ¹⁴
8	TRIP12	Thyroid Hormone Receptor Interactor 12	Protein Coding	5.5	DISEASES inferred ¹⁴
9	ZNF583	Zinc Finger Protein 583	Protein Coding	5.35	DISEASES inferred ¹⁴
10	TASOR2	Transcription Activation Suppressor Family Member 2	Protein Coding	5.33	DISEASES inferred ¹⁴
11	TP53	Tumor Protein P53	Protein Coding	5.23	DISEASES inferred ¹⁴
12	CD8A	CD8a Molecule	Protein Coding	5.15	DISEASES inferred ¹⁴
13	KRT7	Keratin 7	Protein Coding	5.15	DISEASES inferred ¹⁴
14	ZNF599	Zinc Finger Protein 599	Protein Coding	5.08	DISEASES inferred ¹⁴
15	EGFR	Epidermal Growth Factor Receptor	Protein Coding	4.93	DISEASES inferred ¹⁴
16	PLK3	Polo Like Kinase 3	Protein Coding	4.91	DISEASES inferred ¹⁴
17	FBXW7	F-Box And WD Repeat Domain Containing 7	Protein Coding	4.9	DISEASES inferred ¹⁴

Sources

Variations for Anal Squamous Cell Carcinoma

Sources

Expression for Anal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Anal Squamous Cell Carcinoma.

Sources

Pathways for Anal Squamous Cell Carcinoma

Pathways related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.31	TP53 PIK3CA EGFR CD4
2	Malignant pleural mesothelioma ⁷⁴	12.27	TP53 PIK3CA EGFR CDKN2A CD274
3	CD28 co-stimulation ⁶⁶ Show member pathways Activation of AKT2 ⁶⁶ CD28 dependent PI3K/Akt signaling ⁶⁶ CD28 dependent Vav1 pathway ⁶⁶ Costimulation by the CD28 family ⁶⁶ CTLA4 Signaling ⁶⁴ VEGFR2 mediated vascular permeability ⁶⁶	12.09	PIK3CA CD8A CD4 CD274
4	Gastrin signaling pathway ⁷⁴	11.68	PIK3CA EGFR CDKN2A
5	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.34	TP53 PIK3CA FBXW7
6	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	11.2	TP53 PIK3CA CDKN2A CD8A CD4
7	Head and neck squamous cell carcinoma ⁷⁴	11.12	TP53 PIK3CA EGFR CDKN2A
8	Bladder cancer ⁷⁴	10.93	TP53 EGFR CDKN2A
9	Relationship between inflammation, COX-2 and EGFR ⁷⁴	10.43	PIK3CA EGFR
10	PLK3 signaling events ⁶¹	10.1	TP53 PLK3